Chronic stress promotes gastric cancer progression via the adrenoceptor beta 2/PlexinA1 pathway.

BACKGROUND: Chronic stress is a common emotional disorder in cancer patients. Chronic stress promotes progression of gastric cancer (GC) and leads to poor outcomes. However, the underlying mechanisms remain not clear. Herein, we explored the possible mechanisms of chronic stress in GC progression.

METHODS: TCGA datasets were analyzed for differentially expressed genes. Clinical data of GC were evaluated for their association with PlexinA1 using The Cancer Genome Atlas (TCGA) and Kaplan-Meier (KM)-plotter databases. Chronic stress of GC patients was evaluated using the Self-Rating Anxiety Scale and Self-Rating Depression Scale. Chronic unpredictable mild stress (CUMS) was used to induce chronic stress in mice. Gastric xenograft tumor was constructed using the sewing method. Chronic stress-like behaviors were assessed using light/dark box and tail suspension tests. Protein expression was detected using immunohistochemistry and Western blot analysis.

RESULTS: Analyses of TCGA and the KM-plotter databases showed that patients with high levels of PlexinA1 in GC had worse overall survival than those with low levels of PlexinA1. A total of 36 GC patients were enrolled in the study, and about 33% of the patients had chronic stress. Compared with patients without chronic stress, higher expression levels of adrenoceptor beta 2 (ADRB2) and PlexinA1 were observed in patients with chronic stress. The tumor size in mice under CUMS was significantly increased compared with the control mice. ADRB2, PlexinA1, N-cadherin, and alpha-smooth muscle actin (α-SMA), as well as Ki67 were highly expressed in the tumors of CUMS group. However, E-cadherin was lowly expressed in the tumors of CUMS group. Importantly, chemical sympathectomy with 6-hydroxydopamine (6-OHDA) or treatment with a selective β2 adrenergic receptor antagonist (ICI118,551) could reverse these effects.

CONCLUSIONS: Our findings suggest that chronic stress plays an important role in GC progression and there is a potential for blocking the epinephrine-β2AR/PlexinA1 pathway in the treatment of GC.